Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA
16.5.2019 19:00:00 EEST | Business Wire | Press release
Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31-June 4, 2019, in Chicago, Illinois; and the 24th Congress of the European Hematology Association (EHA), to be held June 13-16, 2019, in Amsterdam, the Netherlands.
Abstracts accepted for presentation at ASCO feature genomic profiling data from Incyte’s ongoing Phase 2 FIGHT-202 trial evaluating its selective fibroblast growth factor receptor (FGFR) inhibitor, pemigatinib, in patients with cholangiocarcinoma, as well as efficacy and safety data from the Novartis-sponsored GEOMETRY mono-1 trial of capmatinib, the investigational selective MET inhibitor licensed to Novartis by Incyte. Additionally, data to be presented at EHA will showcase the continued study of Incyte’s JAK1/JAK2 inhibitor, ruxolitinib, in myeloproliferative neoplasms (MPNs).
"Our presence at ASCO and EHA illustrates Incyte’s ongoing commitment to discovering and developing therapeutic options that address significant unmet medical needs for patients,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “We are pleased to highlight new data on two investigational medicines – pemigatinib and capmatinib – that were discovered by Incyte scientists and for which we anticipate applications for initial U.S. regulatory approvals later this year, as well as data that furthers our understanding of the treatment of MPNs.”
Key ASCO and EHA abstracts include:
ASCO Abstracts
Oral Presentation
Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1 study (Abstract #9004, oral abstract session)
- Monday, June 3, 2019, 9:12 – 9:24 a.m. CT, Hall B1
Poster Presentation
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma (Abstract #4080, poster session)
- Monday, June 3, 2019, 8:00 – 11:00 a.m. CT, Hall A
EHA Abstracts
Poster Presentations
Impact of myeloproliferative neoplasms (MPNS) and perceptions of treatment goals amongst physicians and patients in 6 countries: an expansion of the MPN Landmark Survey (Abstract #PF681, poster presentation)
- Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area
Real-world safety data from a non-interventional long-term post authorization safety study of ruxolitinib in myelofibrosis (Abstract #PF679, poster presentation)
- Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area
Safety and efficacy of ruxolitinib (RUX) in patients with myelofibrosis (MF) and anemia (hemoglobin <10g/dL): Results at Week 24 of the REALISE trial (Abstract #PS1465, poster presentation)
- Saturday, June 15, 2019, 5:30 – 7:00 p.m. CEST, Poster area
For full session details and data presentation listings, please see the ASCO (https://iplanner.asco.org/am2019) and EHA (https://learningcenter.ehaweb.org/eha) online programs.
Where the use of compounds described herein is either investigational or being studied for (a) new use(s), efficacy and safety have not been established, and there is no guarantee that such compounds will become commercially available for the use(s) under investigation.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s development pipeline and whether or when any development compounds will be approved for use in humans anywhere in the world, its presentation plans for the upcoming ASCO and EHA annual meetings and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ending March 31, 2019. Incyte disclaims any intent or obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005849/en/
Contact information
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify's Q2 Global Air Travel Fraud Report Finds Fraud Pressure Intensifying Across Middle East and Africa15.7.2026 14:00:00 EEST | Press release
Accertify, a leading fraud decisioning provider whose Predictive Yes Platform helps merchants say yes to more good customers, more revenue, and more growth, today announced the release of its Global Air Travel Fraud Report: Q2 2026, a quarterly analysis examining how fraud pressure varies across global airline markets based on departure city at time of booking. Based on analysis of 132.9 million airline booking transactions processed between April and June 2026, the report evaluates prevented fraud rates across 537 departure cities that each processed at least 10,000 transactions during the quarter, providing airlines with a data-driven view of where Accertify's Predictive Yes platform intervened most frequently at booking. The Q2 findings reveal that fraud pressure continues to vary significantly by market, with the most notable shift occurring across the Middle East and Africa. The region's average prevented fraud rate more than doubled quarter over quarter, from 0.95% to 2.03% — the
Forrester’s 2027 Budget Planning Guides: After A Year Of Caution, Business And Tech Leaders Are Ready To Invest Again15.7.2026 12:00:00 EEST | Press release
According to Forrester’s (Nasdaq: FORR) 2027 Budget Planning Guides, business and technology leaders are approaching 2027 with renewed confidence as they increasingly accept volatility as a permanent feature of the business environment. After a year of more cautious spending, more than 80% of leaders expect their budgets to increase over the next 12 months, with as many as one-quarter anticipating growth of 10% or more. But planning in the age of AI demands more than bigger budgets: Increasing investment without modernizing operating models, strengthening data foundations, and improving AI readiness will only accelerate fragmented data, duplicated work, and technical debt. To realize AI’s full potential, leaders must rethink their strategies and prioritize investments in operational foundations, governance, and experimentation that drive tangible outcomes. This year, optimism is widespread across functions: 82% of technology decision-makers and 91% of marketers expect budget increases
Post-Quantum’s Algorithm - Classic McEliece - Achieves Global ISO Standardization to Protect the World From Quantum Cyber Attack15.7.2026 11:00:00 EEST | Press release
It’s proven that today’s encryption is vulnerable to attack by a sufficiently mature quantum computer running Shor’s algorithm - a catastrophic event commonly known as Q-Day. Even before such a cryptographically relevant quantum computer emerges it is known that adversaries are stealing encrypted data now, which can be decrypted later - also known as Harvest Now, Decrypt Later (HNDL). Google’s recent use of Artificial Intelligence (AI) to optimise Shor’s algorithm reduces the number of physical qubits required to break today’s encryption, therefore shortening the timeline to Q-Day. This has led prominent experts to estimate today’s encryption may be broken as-soon-as the next three years. It’s against this backdrop that the International Organisation for Standardisation (ISO) has included the Classic McEliece algorithm as part of its standard for Asymmetric Ciphers (ISO/IEC 18033-2). Organisations from ISO’s 177 member states can now upgrade to Classic McEliece using an international s
Thredd Joins The Visa Agentic Ready Programme, Bringing Agent Network Readiness To Issuers Across Europe, Starting With Zilch15.7.2026 10:00:00 EEST | Press release
Thredd, the AI-first issuer processing platform, today announced it has joined the Visa Agentic Ready programme, enabling issuers across Europe to participate in agent-initiated payments without rebuilding their payments infrastructure. Consumer payments platform Zilch will be among the first issuers on the platform to enable agent-initiated payments for its cardholders. As a processor and enabler, Thredd sits at the trust layer of the payments ecosystem. By joining the programme, Thredd is ready to support Visa and its clients as the market moves into agentic commerce. Agentic commerce introduces a new type of payment initiator: An AI agent acting on a cardholder's behalf. The core payments principles do not change. Cardholder permission, issuer approval, authentication and fraud monitoring all still apply. What changes is how trust is established and enforced at the point an agent transacts. Taking a Zilch customer as an example, a cardholder might ask an AI agent to find a product w
Surgerii Robotics Announces First European Installation of the SHURUI ® Single-Port Surgical System at Vall d'Hebron University Hospital15.7.2026 10:00:00 EEST | Press release
Surgerii Robotics today announced the first European installation of its SHURUI Single-Port (SP) Surgical System at Vall d'Hebron University Hospital in Barcelona, Spain, one of Europe's leading academic medical centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713209503/en/ The first pediatric procedure performed with the SHURUI SP system was a nephroureterectomy on a twelve-year-old boy whose kidney and ureter had become infected and non-functional due to multiple stones. The SHURUI SP system is CE-marked for adult and pediatric use, making it the only CE-marked single-port robotic surgical system currently indicated for pediatric procedures in Europe. The installation marks an important milestone in the international expansion of Surgerii Robotics and the introduction of the technology into a major European reference center. As part of this collaboration, Vall d'Hebron University Hospital has become the first hos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom